Search

Displaying results 1471 - 1480 of 2674 in total
  1. Drug

    Ginsenoside Rb1

    go.drugbank.com/drugs/DB06749
    ExperimentalNutraceutical

    Recent research shows that Rb1 affects rat embryo development and has teratogenic effects, causing birth defects.

  2. Target

    Glycine receptors

    go.drugbank.com/bio_entities/BE0009666
    TargetHumans

    Subunit of heteromeric glycine-gated chloride channels (PubMed:14551753, PubMed:23994010, PubMed:25730860, PubMed:37821459). Plays an important role in the down-regulation of neuronal excitability (PubMed:8298642, PubMed:9009272). Contri...

    Synonyms: Glycine receptor 48 kDa subunit, Glycine receptor 58 kDa subunitPolypeptides: Glycine receptor subunit alpha-1, Glycine receptor subunit beta
  3. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent remov...

  4. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).

    Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody Interactions
  5. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  6. Drug

    Clonidine

    go.drugbank.com/drugs/DB00575
    ApprovedInvestigational

    [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]

    Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  7. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.

  8. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.

  9. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

    Categories: Tumor Necrosis Factor Receptor Blocking Activity
  10. Drug

    Anidulafungin

    go.drugbank.com/drugs/DB00362
    Approved

    Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.